Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia

INTRODUCTION: Diffuse large B-cell lymphoma (dlbcl) accounts for 30%–40% of all non-Hodgkin lymphomas. Approximately 60% of patients are cured with standard treatment. Targeted treatments are being investigated and might improve disease outcomes; however, their effect on cancer drug budgets will be...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Curr Oncol
Autors principals: Costa, S., Scott, D.W., Steidl, C., Peacock, S.J., Regier, D.A.
Format: Artigo
Idioma:Inglês
Publicat: Multimed Inc. 2019
Matèries:
Costing Series
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6476431/
https://ncbi.nlm.nih.gov/pubmed/31043812
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.26.4565
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars